热门资讯> 正文
管弦乐团BioMed报告财政年度业绩
2024-03-28 04:52
- Orchestra BioMed press release (NASDAQ:OBIO): Net loss for 2023 was $49.1 million, or ($1.48) per share, compared with a net loss of $33.6 million, or ($2.24) per share, for 2022.
- Revenue for 2023 was $2.8 million, compared with $3.5 million for 2022.
- Cash and cash equivalents and marketable securities totaled $87.6 million as of December 31, 2023. Expected runway extended into the second half of 2026 based on internally prepared forecast reflecting updated operating priorities and certain potential future proceeds.
More on Orchestra BioMed
- Jefferies starts Orchestra BioMed at buy, cites lead program opportunities
- Seeking Alpha’s Quant Rating on Orchestra BioMed
- Historical earnings data for Orchestra BioMed
- Financial information for Orchestra BioMed
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
